By the end of 2020, with our respective collaboration partners, Novartis and MorphoSys, we could see two additional new product approvals with capmatinib as a treatment for certain patients with metastatic non small cell lung cancer and tafasitamab for relapsed refractory DLBCL, both of which are under priority review with the FDA.But so, we just go by the clinical trials and approximately six months is what we believe for the duration of therapy for acute steroid-refractory GVHD Steven H. Stein -- Executive Vice President and Chief Medical Officer And for your second question in terms of the LIMBER program and the potential ability to reach more patients with MF, I think the clean answer is yes.